LPL Financial LLC Increases Stock Holdings in Takeda Pharmaceutical Co. (NYSE:TAK)

LPL Financial LLC increased its holdings in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 7.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 201,433 shares of the company’s stock after buying an additional 14,781 shares during the period. LPL Financial LLC’s holdings in Takeda Pharmaceutical were worth $2,995,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. FNY Investment Advisers LLC purchased a new position in Takeda Pharmaceutical in the 1st quarter valued at $37,000. Farther Finance Advisors LLC lifted its holdings in Takeda Pharmaceutical by 29.2% in the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company’s stock valued at $69,000 after purchasing an additional 1,045 shares in the last quarter. Fifth Third Bancorp lifted its holdings in Takeda Pharmaceutical by 85.5% in the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company’s stock valued at $78,000 after purchasing an additional 2,411 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in Takeda Pharmaceutical in the 4th quarter valued at $94,000. Finally, GAMMA Investing LLC lifted its holdings in Takeda Pharmaceutical by 22.6% in the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock valued at $105,000 after purchasing an additional 1,296 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Up 1.3%

Shares of TAK stock opened at $14.99 on Friday. The stock’s fifty day moving average is $14.79 and its two-hundred day moving average is $14.62. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.59 and a current ratio of 1.16. The firm has a market capitalization of $47.70 billion, a P/E ratio of 49.97 and a beta of 0.22. Takeda Pharmaceutical Co. has a fifty-two week low of $12.80 and a fifty-two week high of $15.53.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The company had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. Research analysts expect that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.